Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

Related Experiment Videos

P Bramanti1, E Sessa, C Rifici

  • 1Centro per lo Studio ed il Trattamento dei Neurolesi Lungodegenti, Cattedra di Neurofisiopatologia, University of Messina, Italy.

Neurology
|December 17, 1998
PubMed

Insights

Interferon beta-1b (IFNbeta-1b) treatment may worsen spasticity in patients with multiple sclerosis (MS). Further research is essential before widespread use in primary progressive MS patients.

Area of Science:

  • Neuroimmunology
  • Neurology
  • Multiple Sclerosis Research

Background:

  • Spasticity is a common and disabling symptom in multiple sclerosis (MS).
  • Interferon beta-1b (IFNbeta-1b) is a treatment used for MS, but its effects on spasticity are not fully understood.

Purpose of the Study:

  • To investigate the effect of interferon beta-1b (IFNbeta-1b) treatment on spasticity in patients with primary progressive multiple sclerosis (PPMS).

Main Methods:

  • A cohort of 19 patients with primary progressive MS received IFNbeta-1b treatment.
  • A control group of 19 patients with primary progressive MS did not receive IFNbeta-1b treatment.
  • Spasticity levels and antispasticity medication requirements were monitored.

Main Results:

  • Thirteen out of 19 patients (68%) treated with IFNbeta-1b experienced an enhancement of spasticity.
  • Patients with increased spasticity required higher doses of antispasticity medications.

Conclusions:

  • Interferon beta-1b (IFNbeta-1b) treatment may exacerbate spasticity in primary progressive MS patients.
  • The findings suggest caution regarding the widespread use of interferons in this patient population.
  • Further studies are warranted to clarify the risks and benefits of IFNbeta-1b in PPMS.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...